Boris Julien

TL;DR: The study shows that CB1 receptor antagonists hold promise for the treatment of liver fibrosis, and suggests that endocannabinoids may drive both CB2-mediated antifibrogenic effects andCB2-independent profibrogenics effects.

TL;DR: These data constitute the first demonstration that CB2 receptors are highly up-regulated in the cirrhotic liver, predominantly in hepatic fibrogenic cells and highlight the antifibrogenic role of CB2 receptor during chronic liver injury.

TL;DR: A review highlights recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged.

TL;DR: It is shown that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients, support a pivotal role for CB( 2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington’s disease as well as in other Neurodegenerative disorders with a significant excitotoxic component.

TL;DR: Daily cannabis smoking is significantly associated with fibrosis progression during chronic hepatitis C (CHC), and patients with ongoing CHC should be advised to refrain from regular cannabis use.